2026.6000 21.80 (1.09%)
NSE Jun 11, 2025 15:31 PM
Volume: 983.2K
 

2026.60
1.09%
Axis Direct
Niche product approvals and a strong pipeline of new drugs could drive Revenue/PAT CAGR by 10%/19.5% over FY24E-FY26E. We maintain our BUY rating with a Target Price of Rs 1,770/share.
Number of FII/FPI investors increased from 964 to 979 in Mar 2025 qtr.
More from Lupin Ltd.
Recommended